Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)

Abstract Objective: To re-examine the use of noncarbapenems (NCBPs), specifically piperacillin-tazobactam (PTZ) and cefepime (FEP), for extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (ESBL-E BSIs). Design: Retrospective cohort study. Setting: Tertiary-care,...

Full description

Bibliographic Details
Main Authors: Catherine H. Vu, Veena Venugopalan, Barbara A. Santevecchi, Stacy A. Voils, Reuben Ramphal, Kartikeya Cherabuddi, Kathryn DeSear
Format: Article
Language:English
Published: Cambridge University Press 2022-01-01
Series:Antimicrobial Stewardship & Healthcare Epidemiology
Online Access:https://www.cambridge.org/core/product/identifier/S2732494X22000213/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S2732494X22000213/type/journal_article

Similar Items